|
|
|
|
|
Received: 15 February 2025
|
|
|
|
|
|
[1] 吴莉芳. 阿莫西林联合奥美拉唑治疗胃炎合并胃溃疡的临床效果[J].临床合理用药杂志,2023,16(2):74-76.
[2] 高跃霖,吴小玲.四联疗法与三联疗法治疗幽门螺杆菌胃炎合并胃溃疡的临床效果观察[J].北方药学,2024,21(06):188-190.
[3] 高春,江晶晶,毛军峰,等.基于伏诺拉生与基于质子泵抑制剂的三联疗法根除幽门螺杆菌的有效性和安全性Meta分析[J].胃肠病学和肝病学杂志,2023,32(04):421-427.
[4] 王静燕,方宏图,汪晓静,等.半夏泻心汤加减方对幽门螺杆菌相关性胃炎患者氧化应激指标及血清微小RNA-155可溶性白细胞介素-2受体的影响[J].中国药物与临床,2024,24(18):1163-1168.
[5] 中华中医药学会脾胃病分会.慢性胃炎中医诊疗专家共识意见(2017)[J].中华中医药杂志,2017,32(7):3060-3064.
[6] 倪伟. 内科学[M].北京:中国中医药出版社,2012:507.
[7] 郑筱萸. 中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:134-139.
[8] 中华医学会消化病学分会.中国慢性胃炎共识意见[J].胃肠病学,2006,5(11):44-55.
[9] Sun Q,Yuan C,Zhou S,et al. Helicobacter pylori infection:a dynamic process from diagnosis to treatment[J].Front Cell Infect Microbiol.2023,13:1257817.
[10] Leja M,Grinberga-Derica I,Bilgilier C,,et al. Review:Epidemiology of Helicobacter pylori infection[J].Heli-cobacter.. Review:Epidemiology of Helicobacter pylori infection[J].Heli-cobacter.2019,24 Suppl 1:e12635.
[11] 陈嘉琳,曾庆新,邱锋.不同Hp感染状态及胃黏膜病变对血清胃蛋白酶原、胃泌素水平的影响[J].医学理论与实践,2021,34(9):1564-1566. |
| [1] |
Tian Lu, Ruan Zheng, Guo Yuping. Study on the Relationship between miRNA-146a Expression in Peripheral Blood Mononuclear Cells and Oxidative Stress Levels and Inflammatory Response in Patients with Chronic Obstructive Pulmonary Disease[J]. journal1, 2025, 45(1): 1-4. |
| [2] |
. [J]. journal1, 2024, 44(1): 73-75. |
| [3] |
. [J]. journal1, 2024, 44(1): 122-124. |
| [4] |
. [J]. journal1, 2023, 43(5): 52-54. |
| [5] |
Zhang Ruimei, Li Mingming, Ma Kaiyue. Efficacy of Ipratropium Bromide Combined with Ceftazidime in the Treatment of Chronic Obstructive Pneumonia[J]. journal1, 2022, 42(5): 16-18. |
| [6] |
. [J]. journal1, 2022, 42(3): 134-135. |
|
|
|
|
2025, Vol. 45 
